Lixte Biotechnology Holdings Inc.’s LIXT main clinical molecule, LB-100, enhanced the receptivity of various tumors to immunotherapy in preclinical tests.
In mice models of colorectal, triple-negative breast, and pancreatic cancer, treatment with LB-100 was linked with novel antigen generation, tumor infiltration of cytotoxic T cells, and improved responsiveness to immune checkpoint blockade, according to the findings.
“The results of Yen et al. raise the prospect that adding LB-100 to immunotherapy may be a straightforward strategy to turn ‘cold’ tumors into ‘hot’ tumors, hence increasing the percentage of patients receptive to immunotherapy,” stated John S. Kovach, Lixte’s founder, and CEO.
In a new experiment, Lixte is combining LB-100 with chemotherapy and an immune checkpoint blocker in patients with advanced-stage small cell lung cancer, and then administering the immune checkpoint blocker alone in the maintenance phase of treatment.
The company is interested in participating in collaborative trials to see if LB-100 can improve the efficacy of immunotherapy in a broad sense.
Price Action: LIXT shares are currently trading at $2.99, up 121.5 percent since the last market check on Wednesday.